Zymeworks Inc. (NASDAQ:ZYME) Q1 2022 Results Conference Call May 4, 2022 4:30 PM ET
Company Participants
Jack Spinks - Associate Director of Investor Relations
Neil Klompas - Chief Operating Officer
Kenneth Galbraith - Chair and CEO
Chris Astle - SVP and CFO
Neil Josephson - CMO
Conference Call Participants
Stephen Willey - Stifel
Charles Zhu - Guggenheim Securities
Josh Schimmer - Evercore
Nick Abbott - Well Fargo
Akash Tewari - Jefferies
David Martin - Bloom Burton
Operator
Good day and thank you for standing by. Welcome to Zymeworks First Quarter 2022 Results Conference Call. At this time, all participants are in listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]
Now, it is my pleasure to hand a conference over to your first speaker today, Jack Spinks, Head of Investor Relations. Thank you. Please go ahead.
Jack Spinks
Good afternoon, and welcome everyone. My name is Jack Spinks, Associate Director of Investor Relations here at Zymeworks. Today, we will discuss our first quarter 2022 financial results as well as provide an update to our ongoing business.
Before we begin, I would like to remind you that we will be making a number of forward-looking statements during this call, including statements that relate to the implementation of our strategic priorities. Clinical development of our product candidates, related clinical trials, anticipated clinical data presentations, potential therapeutic effects of zanidatamab and our other product candidates, expected financial performance and future financial position, the commercial potential of technology platforms and product candidates anticipated continued receipt of revenue from existing in future partners, our preclinical pipeline, anticipated sufficiency of cash resources and other potential sources of cash to fund our planned operations into the second half of 2023 and potentially beyond, our ability to execute new collaborations and partnerships and other information that is not historical information.
Forward-looking statements are based upon our current expectations and various assumptions and our subject to the usual risks and uncertainties associated with companies in our industry and at our stage of development. For a discussion of these risks and uncertainties, we refer you to our latest SEC filings as found on our website and as filed with the SEC.
Later in this call, Neil Klompas, our Chief Operating Officer will be discussing our financial results, including certain non-GAAP measures. A description of our non-GAAP measures and a reconciliation to the most directly comparable financial results as determined in accordance with GAAP are described in detail in our press release, which is available on our website at www.zymeworks.com under the Investor Relations tab. As a reminder, the audio and slides from this call will be available on the Zymeworks' website later today.